<p>4D Molecular Therapeutics（纳斯达克代码：FDMT - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$1.01），超出分析师一致预期的（$1.02）$0.01，Zacks 报道。4D Molecular Therapeutics 的净利润率为负的 594,375.81%，股本回报率为负的 40.15%。该季度的营业收入为 9 万美元，而一致预期为 40 万美元。</p>
<h2>4D Molecular Therapeutics 股票表现</h2>
<p>4D Molecular Therapeutics 的股票在周二的交易时段上涨了 0.63 美元，达到了 10.80 美元。该公司的股票交易量为 1,824,237 股，而其平均交易量为 860,096 股。该股票的市值为 5.0436 亿美元，市盈率为-3.06，贝塔值为 2.96。4D Molecular Therapeutics 的 12 个月最低价为 2.23 美元，最高价为 12.34 美元。该公司的 50 日移动平均价为 8.99 美元，200 日移动平均价为 6.09 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>FDMT 最近成为几份研究报告的主题。摩根士丹利在周五的研究报告中将 4D Molecular Therapeutics 的评级从 “减持” 上调至 “持平”。Chardan Capital 在周二将 4D Molecular Therapeutics 的目标价从 25.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。巴克莱在周二将 4D Molecular Therapeutics 的目标价从 38.00 美元下调至 33.00 美元，并对该股票给予 “增持” 评级。加拿大皇家银行在周二将 4D Molecular Therapeutics 的目标价从 26.00 美元上调至 32.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Leerink Partners 在 10 月 31 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 17.00 美元的目标价。八位投资分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，4D Molecular Therapeutics 的共识评级为 “适度买入”，平均目标价为 28.70 美元。</p>
<p><strong>查看我们关于 4D Molecular Therapeutics 的最新报告</strong></p>
<h2>内部人士买卖</h2>
<p>在其他 4D Molecular Therapeutics 的新闻中，内部人士 Scott Bizily 在 10 月 24 日的交易中出售了 2,678 股公司的股票。这些股票以每股 12.00 美元的平均价格出售，总价值为 32,136.00 美元。交易后，该内部人士持有 3,594 股公司的股票，价值为 43,128 美元。这代表了他们持股比例的 42.70% 的减少。该交易在向 SEC 提交的文件中披露，文件可通过此链接获取。过去 90 天内，内部人士共出售了 9,128 股公司股票，价值为 92,100 美元。公司内部人士持有公司 9.60% 的股份。</p>
<h2>对 4D Molecular Therapeutics 的对冲基金看法</h2>
<p>几家大型投资者最近对 FDMT 的持仓进行了调整。Dynamic Technology Lab Private Ltd 在第一季度获得了 4D Molecular Therapeutics 的新股份，价值约 39,000 美元。AQR Capital Management LLC 在第一季度获得了 4D Molecular Therapeutics 的新股份，价值 46,000 美元。Rangeley Capital LLC 在第二季度获得了 4D Molecular Therapeutics 的新股份，价值 48,000 美元。Russell Investments Group Ltd.在第二季度将其在 4D Molecular Therapeutics 的持股增加了 11.7%。Russell Investments Group Ltd.现在持有 21,816 股公司的股票，价值 81,000 美元，此前在该期间内又购买了 2,284 股。最后，Bridgeway Capital Management LLC 在第二季度将其在 4D Molecular Therapeutics 的持股增加了 100.3%。Bridgeway Capital Management LLC 现在持有 25,000 股公司的股票，价值 93,000 美元，此前在上个季度又收购了 12,516 股。目前 99.27% 的股票由机构投资者和对冲基金持有。</p>
<h2>4D Molecular Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>4D Molecular Therapeutics, Inc 是一家临床阶段的生物治疗公司，利用其治疗性载体进化平台在荷兰和美国开发基因药物。该公司开发了一系列基因药物候选产品，专注于眼科、心脏病学和肺病学三个治疗领域。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 4D Molecular Therapeutics 更好</li>
<li>如何利用分析师评级进行交易</li>
<li>下跌 25%，国防明星 Kratos 是否是一个有吸引力的机会？</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>Rumble 以 7.67 亿美元收购标志着大胆转向 AI 基础设施</li>
<li>大型股定义及如何投资</li>
<li>软银退出 NVIDIA——那又如何？分析师仍然看到更多上涨空间</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkRNVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkRNVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 4D Molecular Therapeutics 吗？</h2>
<p>在你考虑 4D Molecular Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 4D Molecular Therapeutics 并不在名单上。</p>
<p>虽然 4D Molecular Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

FDMT

<p>4D Molecular Therapeutics（纳斯达克代码：FDMT）报告季度每股收益为（$1.01），超出预期的（$1.02）$0.01。该公司的收入为$0.09 百万，低于预期的$0.40 百万。尽管股本回报率为负的 40.15% 和净利润率为 594,375.81%，但股价上涨至$10.80。分析师的评级意见不一，普遍共识为 “适度买入”，平均目标价为$28.70。近期内部人士的卖出和显著的机构持股被提及，99.27% 的股份由机构投资者持有</p>

<p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) issued its earnings results on Monday. The company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.01, Zacks reports. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics（纳斯达克代码：FDMT - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$1.01），超出分析师一致预期的（$1.02）$0.01，Zacks 报道。4D Molecular Therapeutics 的净利润率为负的 594,375.81%，股本回报率为负的 40.15%。该季度的营业收入为 9 万美元，而一致预期为 40 万美元。</p>
</div><h2>4D Molecular Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 股票表现</h2>
</div><p>Shares of 4D Molecular Therapeutics stock traded up $0.63 during trading hours on Tuesday, hitting $10.80. The company's stock had a trading volume of 1,824,237 shares, compared to its average volume of 860,096. The stock has a market cap of $504.36 million, a price-to-earnings ratio of -3.06 and a beta of 2.96. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The firm has a fifty day moving average of $8.99 and a 200-day moving average of $6.09.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics 的股票在周二的交易时段上涨了 0.63 美元，达到了 10.80 美元。该公司的股票交易量为 1,824,237 股，而其平均交易量为 860,096 股。该股票的市值为 5.0436 亿美元，市盈率为-3.06，贝塔值为 2.96。4D Molecular Therapeutics 的 12 个月最低价为 2.23 美元，最高价为 12.34 美元。该公司的 50 日移动平均价为 8.99 美元，200 日移动平均价为 6.09 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>FDMT has been the subject of several recent research reports. Morgan Stanley raised 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research report on Friday. Chardan Capital lifted their price target on 4D Molecular Therapeutics from $25.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Barclays dropped their price objective on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday. Royal Bank Of Canada lifted their price target on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday. Finally, Leerink Partners reissued an &#34;outperform&#34; rating and set a $17.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $28.70.</p>
<div class="lb-trans"><p>FDMT 最近成为几份研究报告的主题。摩根士丹利在周五的研究报告中将 4D Molecular Therapeutics 的评级从 “减持” 上调至 “持平”。Chardan Capital 在周二将 4D Molecular Therapeutics 的目标价从 25.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。巴克莱在周二将 4D Molecular Therapeutics 的目标价从 38.00 美元下调至 33.00 美元，并对该股票给予 “增持” 评级。加拿大皇家银行在周二将 4D Molecular Therapeutics 的目标价从 26.00 美元上调至 32.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Leerink Partners 在 10 月 31 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 17.00 美元的目标价。八位投资分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，4D Molecular Therapeutics 的共识评级为 “适度买入”，平均目标价为 28.70 美元。</p>
</div><p><strong>View Our Latest Report on 4D Molecular Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 4D Molecular Therapeutics 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the company's stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the transaction, the insider owned 3,594 shares of the company's stock, valued at $43,128. This represents a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 9,128 shares of company stock valued at $92,100 over the last 90 days. Corporate insiders own 9.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 4D Molecular Therapeutics 的新闻中，内部人士 Scott Bizily 在 10 月 24 日的交易中出售了 2,678 股公司的股票。这些股票以每股 12.00 美元的平均价格出售，总价值为 32,136.00 美元。交易后，该内部人士持有 3,594 股公司的股票，价值为 43,128 美元。这代表了他们持股比例的 42.70% 的减少。该交易在向 SEC 提交的文件中披露，文件可通过此链接获取。过去 90 天内，内部人士共出售了 9,128 股公司股票，价值为 92,100 美元。公司内部人士持有公司 9.60% 的股份。</p>
</div><h2>Hedge Funds Weigh In On 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>对 4D Molecular Therapeutics 的对冲基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the 1st quarter valued at approximately $39,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at $46,000. Rangeley Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at $48,000. Russell Investments Group Ltd. raised its holdings in shares of 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock valued at $81,000 after buying an additional 2,284 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in 4D Molecular Therapeutics by 100.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company's stock worth $93,000 after acquiring an additional 12,516 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家大型投资者最近对 FDMT 的持仓进行了调整。Dynamic Technology Lab Private Ltd 在第一季度获得了 4D Molecular Therapeutics 的新股份，价值约 39,000 美元。AQR Capital Management LLC 在第一季度获得了 4D Molecular Therapeutics 的新股份，价值 46,000 美元。Rangeley Capital LLC 在第二季度获得了 4D Molecular Therapeutics 的新股份，价值 48,000 美元。Russell Investments Group Ltd.在第二季度将其在 4D Molecular Therapeutics 的持股增加了 11.7%。Russell Investments Group Ltd.现在持有 21,816 股公司的股票，价值 81,000 美元，此前在该期间内又购买了 2,284 股。最后，Bridgeway Capital Management LLC 在第二季度将其在 4D Molecular Therapeutics 的持股增加了 100.3%。Bridgeway Capital Management LLC 现在持有 25,000 股公司的股票，价值 93,000 美元，此前在上个季度又收购了 12,516 股。目前 99.27% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>4D Molecular Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc 是一家临床阶段的生物治疗公司，利用其治疗性载体进化平台在荷兰和美国开发基因药物。该公司开发了一系列基因药物候选产品，专注于眼科、心脏病学和肺病学三个治疗领域。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than 4D Molecular Therapeutics</li>
<li>How to trade using analyst ratings</li>
<li>Down 25%, Is Defense Darling Kratos an Attractive Opportunity?</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Rumble’s $767M Acquisition Marks Bold Pivot Into AI Infrastructure</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>SoftBank Exits NVIDIA—So What? Analysts Still See More Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 4D Molecular Therapeutics 更好</li>
<li>如何利用分析师评级进行交易</li>
<li>下跌 25%，国防明星 Kratos 是否是一个有吸引力的机会？</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>Rumble 以 7.67 亿美元收购标志着大胆转向 AI 基础设施</li>
<li>大型股定义及如何投资</li>
<li>软银退出 NVIDIA——那又如何？分析师仍然看到更多上涨空间</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkRNVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=FDMT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 4D Molecular Therapeutics 吗？</h2>
</div><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 4D Molecular Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 4D Molecular Therapeutics 并不在名单上。</p>
</div><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 4D Molecular Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

4D Molecular Therapeutics (NASDAQ:FDMT) 公布季度财报，每股收益比预期高出 0.01 美元